Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
| Revenue (TTM) | $66.57B |
| Gross Profit (TTM) | $50.53B |
| EBITDA | $28.87B |
| Operating Margin | -0.24% |
| Return on Equity | 6.96% |
| Return on Assets | 11.90% |
| Revenue/Share (TTM) | $26.85 |
| Book Value | $16.99 |
| Price-to-Book | 7.99 |
| Price-to-Sales (TTM) | 5.04 |
| EV/Revenue | 5.74 |
| EV/EBITDA | 26.51 |
| Quarterly Earnings Growth (YoY) | -19.30% |
| Quarterly Revenue Growth (YoY) | 5.10% |
| Shares Outstanding | $2.47B |
| Float | $2.46B |
| % Insiders | 0.06% |
| % Institutions | 82.78% |
Volatility is currently contracting
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial. The combination regimen met the main study goal of significantly extending the time patients lived without their melanoma returning, compared with Keytruda alone, and also reduced the risk of the cancer spreading to distant parts of the body.
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.
RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's a.
AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.
Rose's Income Portfolio yielding 5.6% reached an all-time value high for the third time in July and is up 12.11% YTD. Fifteen/15 portfolio stocks, including MRK, GD, and AMGN, are flagged as overvalued based on proximity to 52-week highs and historic low yields. 5 undervalued candidates for purchase are revealed, supported by both price and historic yield analysis.
Merck (MRK) and GSK face regulatory and manufacturing hurdles to producing individual MMR vaccines, with FDA approval likely to take years. IBM (IBM) is deepening its AI capabilities by integrating OpenAI models into its consulting platform, targeting enterprise AI and cybersecurity solutions.
MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.
President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scientific basis and is unlikely to get off the ground.
Merck's strong Keytruda sales and pipeline progress support its long-term outlook, but falling estimates and patent risks cloud the near term.
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRK and any ticker you trade — then tracks every position and per-strategy win rate.
